Q3 2025 · 13F-HR
Merck & Co., Inc. (MRK)holdings as filed
Filed 2025-11-12 · accession 0000310158-25-000063
$228.0M
Reported value
13
Positions
2025-09-30
Period end
The Brief · Merck & Co., Inc. (MRK) · Q3 2025
AI · grounded in 13F
Merck & Co., Inc. (MRK) established a new position in PSNL valued at $91.6M. The fund also initiated new stakes in MRNA for $59.6M and KYMR for $43.7M. Additional new positions include ALEC at $10.5M and Entrada Therapeutics Inc at $10.1M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 71535D106 | PSNL | PERSONALIS INC | $91.6M | 40.2% | 14,044,943 | Common | SHARED |
| 60770K107 | MRNA | MODERNA INC | $59.6M | 26.1% | 2,308,190 | Common | SHARED |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $43.7M | 19.2% | 772,165 | Common | SHARED |
| 014442107 | ALEC | ALECTOR INC | $10.5M | 4.60% | 3,545,719 | Common | SHARED |
| 29384C908 | TRDA | ENTRADA THERAPEUTICS INC | $10.1M | 4.43% | 1,739,768 | Common | SHARED |
| 29970R204 | EVAXUSD | EVAXION BIOTECH A/S | $4.6M | 2.00% | 1,214,126 | Common | SHARED |
| 869367102 | STRO | SUTRO BIOPHARMA INC | $2.4M | 1.04% | 2,723,509 | Common | SHARED |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $2.0M | 0.88% | 93,414 | Common | SHARED |
| N51517105 | 4PKB | LAVA THERAPEUTICS NV | $1.8M | 0.79% | 1,149,345 | Common | SHARED |
| 98422T100 | XLO | XILIO THERAPEUTICS INC | $1.3M | 0.55% | 1,483,758 | Common | SHARED |
| 14216R101 | CARM | CARISMA THERAPEUTICS INC | $403,668 | 0.18% | 1,473,240 | Common | SHARED |
| 64136E102 | NEUP | NEUPHORIA THERAPEUTICS INC | $118,218 | 0.05% | 10,027 | Common | SHARED |
| 898920103 | HURA | TUHURA BIOSCIENCES | $34,596 | 0.02% | 13,950 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.